Exits Biotech Venture Capital
| Company | Activity | Date of entrance | Date of exit | Buyer | Business unit | |
|---|---|---|---|---|---|---|
|
Pharmaceuticals | 2003 | 2011 | Amgen | Biotech Venture Capital | Info |
|
Biovex Founded in 1998, Biovex develops a new class of vaccines for the treatment of cancer and chronic infectious diseases. The company has two proprietary vaccine platforms (OncoVEX and ImmunoVEX), based on genetic manipulation of the herpes simplex virus (HSV). Biovex recently completed a Phase II clinical trial for the treatment of melanoma with its OncoVEX GM-CSF product. The results of this trial showed that the product was capable of inducing a lasting response in a large proportion of the patients treated. The company is currently carrying out Phase III trials for this indication. In January 2011, Crédit Agricole Private Equity announces Amgen agreement to acquire BioVex for up to US$1 billion. |
||||||
|
Pharmaceuticals | 2006 | 2009 | Pangenetics asset sold to Abbott | Biotech Venture Capital | Info |
|
PanGenetics PanGenetics is a Dutch company dedicated to the clinical development of therapeutic antibodies, which was added to the venture capital portfolio in 2006. The company recently sold exclusive rights to its PG-110 antibody to pharmaceutical group Abbott for $ 190M. Developed by PanGenetics, PG-110 is a humanised anti-NGF antibody. It is currently undergoing phase I clinical trials on patients suffering from chronic pain. The clinical development of this antibody programme was carried out with the support of prestigious investors, including Crédit Agricole Private Equity. To date, the company has raised close to € 51M during the three funding rounds completed between 2005 and 2008. This transaction backs up the company’s original strategy focused on the development of proprietary products and licensing new products, without any R&D activities. |
||||||
|
Pharmaceuticals | 2005 | 2009 | Sanofi Aventis | Biotech Venture Capital | Info |
|
Fovea Privately-held biopharmaceuticals company specialising in the development and marketing of drugs for the treatment of retinal diseases. The company was acquired by Sanofi Aventis for EUR 370 million. |
||||||
|
Pharmaceuticals | 2006 | 2007 | IPO | Biotech Venture Capital | Info |
|
Amsterdam Molecular Therapeutics BV (AMT) Gene therapies for orphan ocular and metabolic diseases. |
||||||
|
Bioproduction | 2002 | 2007 | IPO | Biotech Venture Capital | Info |
|
METabolic EXplorer Created in 1999, METabolic EXplorer is a leading industrial biotechnology company focused on the production of bulk chemicals. The company’s mission is to transform the chemical industry’s value chain by bringing to market more economically and environmentally attractive production processes. In 2002, the participation of Crédit Agricole Private Equity, which acted as the lead manager for the last two private financing rounds and has reinvested significantly in the IPO fund raising, marked a major step in the company's development. METabolic EXplorer has developed a range of proprietary technologies which allow it to build highly efficient bacteria designed to produce existing bulk chemicals from a wide range of renewable feedstocks. This approach based on fermentation methods provide sustainable solutions to the chemical industry, offering significant economic benefits and are more environmental friendly than the current oil-dependent chemical processes. |
||||||
